Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells

3 years ago

LOS ANGELES, March 31, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,…

Cidara Therapeutics to Participate in Upcoming Investor Conferences

3 years ago

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed…

Jasper Therapeutics to Present at Cantor Fitzgerald’s The Future of Oncology Virtual Symposium

3 years ago

REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on development…

TScan Therapeutics Announces CEO Transition

3 years ago

David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as acting CEO Company reaffirms previously…

STRATA Skin Sciences Reports Record Fourth Quarter 2022 Revenue

3 years ago

Achieved record revenue of $36.2 million, representing 21% increase over the year 2021 Company to host conference call and webcast…

Reflect Scientific Inc Announces Year-End Financial Results for 2022

3 years ago

OREM, Utah, March 31, 2023 (GLOBE NEWSWIRE) -- Reflect Scientific Inc (OTCQB: RSCF), a provider of ultra-low temperature freezers and…

Alimera Sciences Announces 2022 Financial Results and Business Update

3 years ago

• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User Demand Increased 22% over 2021…

Immutep Announces Positive Final Data in 2nd Line Metastatic NSCLC Patients Refractory to Anti-PD-(L)1 Therapy at European Lung Cancer Congress 2023

3 years ago

Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare…

NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update

3 years ago

-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and…

Novartis Entresto receives positive CHMP opinion for pediatric heart failure

3 years ago

If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure…